Tocotrienol and Hair Loss

Hair loss news first:

— The same Ohio State University (OSU) doctor who amazed us recently with this breakthrough from his lab is now making claims about hair regeneration from palm tocotrienol complex. I am highly skeptical, but still willing to keep a track of his work because of the OSU affiliation. Tocotrienols are a form of vitamin E.

— Of much more importance, Dr. Tsuji/Kyocera/RIKEN partner Organ Technologies has updated or renewed their website (h/t Fuji Maru Kagurazaka) recently. On their hair follicle regeneration page (after translation), they state:

“We are currently pursuing research and development with a view to clinical application of hair follicle regeneration as the world’s first organ regeneration in humans in 2018”

As an aside, whatever has happened to our invaluable Japanese correspondent/informant “nosyu”? Hope he comes back some day.

— Who else but “nasa_rs” notifying me that Aclaris Therapeutics finally updated their pipeline page. The most interesting part is that they now term their topical JAK inhibitor for androgenetic alopecia (AGA) as a “soft” JAK inhibitor (no surprise), and they term AGA as an “inflammatory” skin disorder. I have theorized for a while that perhaps people who have major itching and dandruff associated with their male pattern hair loss might be suffering from significant inflammation. Therefore, if topical covalently bound JAK inhibitors work for AGA, perhaps they will help those with itchy scalps much more than those without. Aclaris has also started a CEO blog on its site.

— Of least significance, but nevertheless worth mentioning, Follica finally added text to the bios of some of their new team members including Dr. Dhurat.

— Interesting article on the travails of hair loss in UK paper Mosaic.

Androgen receptors have become an increasing area of focus in the hair loss world. A new paper on androgens and androgen receptor action in skin and hair follicles.

— Topical tofacitinib possibly promoting hair growth via VEGF growth factor induction. This is the kind of research that keeps me interested in both JAK inhibitors and platelet-rich plasma (PRP).

— Generation of iPS-derived model cells for analyses of hair shaft differentiation.

And now on to medical items of interest:

China: pig to human organ transplants two years away.

Bionic lens, superhuman threefold vision.

CRISPR changes flower color. Would be great to change untanned Donald Trump into a Sudanese African. That is my political input for the year.

Coma patient communication.

Vaccine to prevent tooth decay.

Aclaris Granted two Patents for JAK Inhibitors and Hair Loss Disorders

Aclaris Therapeutics’ latest e-mail from today morning contained a link to the following press release:

Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders

Quite often, when Aclaris discusses hair loss disorders in its press releases, they only mention alopecia areata (an autoimmune disorder that is responsible for hair loss in 2 percent or so of hair loss sufferers). However, this time they specifically mention androgenetic alopecia (AGA) six different times in their press release so it was worth writing a post on this development. Around 98 percent all men who suffer from hair loss suffer from AGA.

If you are new to this subject matter, make sure to read all the past posts on this blog regarding Aclaris.

Aclaris’ Latest Patents

The two patents that were just granted to Aclaris are highly detailed and informative:

Patent Number 9,737,469 — covers the use of tofacitinib, baricitinib, ruxolitinib and decernotinib, specifically for treating androgenetic alopecia.

Patent Number 9,730,877 — covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.

If you have time, I would encourage you to go through all the “US Patent Document” links in the upper part of the above two patent pages. Those reference documents go all the way from 1998 through 2016. If I had more time, I would search for “androgen” in all those documents and see what comes up.